Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark G Lebwohl

Showing results (131-140 of 209) with videos related to

Pageof 21
Sort By:
Journal of the American Academy of Dermatology|September 22, 2020
Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)Mark G Lebwohl, Craig L Leonardi, Nehal N Mehta, et al.
Journal of the American Academy of Dermatology|April 21, 2009
Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis FoundationC Stanley Chan, Abby S Van Voorhees, Mark G Lebwohl, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 1, 2023
Psychometric validation of the generalized pustular psoriasis physician global assessment (GPPGA) and generalized pustular psoriasis area and severity index (GPPASI)A David Burden, Robert Bissonnette, Mark G Lebwohl, et al.
Dermatology and Therapy|July 29, 2025
Brodalumab: Seven-Year US Pharmacovigilance ReportMark G Lebwohl, John Y Koo, April W Armstrong, et al.
Dermatology and Therapy|May 9, 2024
Brodalumab: 5-Year US Pharmacovigilance ReportMark G Lebwohl, John Y Koo, April W Armstrong, et al.
Journal of the American Academy of Dermatology|September 13, 2017
Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment RegistryDavid Fiorentino, Vincent Ho, Mark G Lebwohl, et al.
Journal of the American Academy of Dermatology|May 7, 2013
A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasisMark G Lebwohl, Leon Kircik, Kristina Callis Duffin, et al.
Journal of the American Academy of Dermatology|January 15, 2017
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanerceptBruce Strober, Alice B Gottlieb, Bintu Sherif, et al.
The British Journal of Dermatology|April 6, 2023
Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposureMark G Lebwohl, Joseph F Merola, Katelyn Rowland, et al.
Journal of the American Academy of Dermatology|November 30, 2020
Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trialAndrew Blauvelt, Mark G Lebwohl, Tomotaka Mabuchi, et al.
Pageof 21

Showing results (131-140 of 209) with videos related to

Sort By:
Pageof 21
Journal of the American Academy of Dermatology|September 22, 2020
Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)Mark G Lebwohl, Craig L Leonardi, Nehal N Mehta, et al.
Journal of the American Academy of Dermatology|April 21, 2009
Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis FoundationC Stanley Chan, Abby S Van Voorhees, Mark G Lebwohl, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 1, 2023
Psychometric validation of the generalized pustular psoriasis physician global assessment (GPPGA) and generalized pustular psoriasis area and severity index (GPPASI)A David Burden, Robert Bissonnette, Mark G Lebwohl, et al.
Dermatology and Therapy|July 29, 2025
Brodalumab: Seven-Year US Pharmacovigilance ReportMark G Lebwohl, John Y Koo, April W Armstrong, et al.
Dermatology and Therapy|May 9, 2024
Brodalumab: 5-Year US Pharmacovigilance ReportMark G Lebwohl, John Y Koo, April W Armstrong, et al.
Journal of the American Academy of Dermatology|September 13, 2017
Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment RegistryDavid Fiorentino, Vincent Ho, Mark G Lebwohl, et al.
Journal of the American Academy of Dermatology|May 7, 2013
A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasisMark G Lebwohl, Leon Kircik, Kristina Callis Duffin, et al.
Journal of the American Academy of Dermatology|January 15, 2017
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanerceptBruce Strober, Alice B Gottlieb, Bintu Sherif, et al.
The British Journal of Dermatology|April 6, 2023
Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposureMark G Lebwohl, Joseph F Merola, Katelyn Rowland, et al.
Journal of the American Academy of Dermatology|November 30, 2020
Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trialAndrew Blauvelt, Mark G Lebwohl, Tomotaka Mabuchi, et al.
Pageof 21